BioStable Science & Engineering, a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, announced today the initial closing of its Series C equity financing.
BioStable Science & Engineering, Inc., a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, today announced that over 500 patients worldwide have now been treated using the HAART Aortic Annuloplasty Device.
BioStable HAART 200 Aortic Annuloplasty Device - Simplifying BAV Repair with Three-Dimensional Annuloplasty. In the inaugural issue of HAARTbeat, we explained how the HAART 300 device was developed from CT angiography studies of normal aortic valves and is designed to create normal three-dimensional annular shape based on leaflet sizing. In BAV disease, there is no such thing as “normal” annular shape and the presentation of the anatomy can be highly variable.
BioStable Science & Engineering, Inc. announced today the first commercial use of the HAART 200 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Drs. Lawrence Wei, Vinay Badhwar and J. Scott Rankin were the collaborating surgeons for the procedure.
BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 200 Aortic Annuloplasty Device, the first and only annuloplasty device designed specifically for bicuspid aortic valve repair.